Allogene Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapies using engineered allogeneic T cells
The company's proprietary platform leverages cutting-edge gene-editing technologies to create off-the-shelf treatments that can be administered to multiple patients, aiming to enhance the body’s immune response against cancer. Through extensive research and clinical trials, Allogene is working to provide effective and accessible options for individuals suffering from various hematologic malignancies and solid tumors, promoting advancements in the field of cell therapy.
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune disease patients but faces challenges in cost and manufacturing.
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQCBAY) rose sharply in today’s pre-market trading.
Allogene Therapeutics Inc (NASDAQALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal trial (ALPHA3) evaluating cema-cel as a consolidation therapy in large B-cell lymphoma (LBCL) patients
